We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s drug pricing watchdog seems to have warmed to AbbVie’s Humira, recommending the drug be covered four months after one of its committees proposed rejecting it.